India Adult Vaccine Market Report

Executive Summary

The adult vaccine market in India differs significantly from the global market in terms of both scale and focus. Globally, vaccines for diseases like influenza, pneumococcal infections, and HPV lead the market due to widespread implementation and high public awareness. In contrast, India’s adult vaccine market has historically lagged behind in these areas but is now gaining momentum, particularly with increased focus on diseases such as hepatitis and pneumococcal infections.

Globally, there has been strong investment in a wide range of adult vaccines, including those for shingles and meningococcal disease. In India, however, the emphasis has been on addressing more immediate health challenges and expanding coverage for prevalent diseases like tuberculosis and hepatitis. Despite this progress, the adult vaccine market in India continues to face challenges, such as lower vaccination rates and less comprehensive coverage compared to high-income countries.

India's aging population has quadrupled over the past 50 years, yet the demand for adult vaccines remains underdeveloped. This gap represents a significant growth opportunity. Strategic investments in adult immunization programs could not only improve public health outcomes but also drive economic benefits by enhancing workforce productivity and reducing healthcare costs associated with preventable diseases.

The country’s total healthcare expenditure, estimated at INR 2,000,000 crore, encompasses government spending, private sector investments, out-of-pocket expenses, and contributions from non-governmental organizations. Within this extensive healthcare framework, expanding adult vaccination coverage could help reduce long-term healthcare costs by preventing disease outbreaks and better managing age-related health risks, benefiting both individuals and the overall economy.

Key Segments in the Adult Vaccine Market

• Influenza: Flu vaccines lead the adult vaccine market due to annual immunizations and increased awareness of respiratory illnesses. In 2023, they remain highly demanded, particularly among high-risk groups in wealthy countries.
• Pneumococcal Disease: Pneumococcal vaccines are crucial for preventing severe infections like pneumonia and meningitis. Growing adoption among aging populations in developed nations is boosting their market presence.
• Human Papillomavirus (HPV): HPV vaccines are increasingly included in adult vaccination programs for preventing cancers related to HPV. The segment is expected to grow as recommendations expand.
• Hepatitis A & B: Vaccines for Hepatitis A and B hold a significant share of the adult vaccine market, driven by greater awareness and government initiatives in both high- and middle-income countries.
• Tetanus, Diphtheria, and Pertussis (Tdap): Tdap vaccines maintain a steady market presence due to booster recommendations for adults and pregnant women, supporting ongoing demand for these disease preventions.
• Shingles (Herpes Zoster): The shingles vaccine market is growing with increased demand from aging populations in developed countries, driven by established immunization programs.

Despite a drop in COVID-19 vaccine purchases in 2022, they still made up of more than 50% of the global vaccine market. Non-COVID vaccines, such as seasonal influenza and tetanus-diphtheria, remained stable at around 5 billion doses, with a rise in measles-rubella vaccines due to catch-up efforts.

Need for Adult Vaccination in India Amidst Rising Health Challenges

Neglect of Adult Vaccinations: Adults often overlook vaccines, especially when the perceived risk is low, and many may have lost immunity or never received vaccinations. In India, vaccination is often only sought due to travel requirements or specific health conditions.

Recommended Vaccines and Guidelines: There are around 85 FDA-approved vaccines for 29 diseases. The CDC recommends vaccines for 15 diseases, including influenza, diphtheria, tetanus, pertussis, and more. The Association of Physicians of India also recommends a similar schedule with the addition of a typhoid vaccine. Most vaccines are recommended based on age and specific criteria rather than universally for all adults.

Investments and Recommendations in Public Health Initiatives

• The allocation of INR 44,160 crore for vaccines is a major public health investment aimed at improving and sustaining immunization efforts, especially in the context of extensive COVID-19 vaccination campaigns.
• Ayushman Bharat stands as the world's largest government-funded health insurance program, offering coverage to nearly 55 crore people from vulnerable backgrounds. Since its inception, over 26,000 hospitals, including more than 11,000 private ones, have been added to the program, enabling 6.2 crore free hospital admissions.
• In June 2024, health and education experts advised the Finance Minister to address the issue of low reimbursement rates within the Ayushman Bharat scheme and to consider providing adult vaccinations at subsidized costs.

Key Regulatory Bodies for Vaccine Approval in India

• Central Drugs Standard Control Organization (CDSCO): CDSCO is India’s national authority for evaluating drug safety, efficacy, and quality, overseeing the approval of biologics and new drugs. It operates under the Drugs and Cosmetics Act of 1940 and its 1945 Rules, with the Drugs Controller General of India (DCGI) at its helm.
• Department of Biotechnology (DBT): DBT is responsible for creating and pre-clinically assessing recombinant biologics via the Review Committee on Genetic Manipulation (RCGM). It works with CDSCO to ensure the safety and efficacy of new biologic products.
• National Technical Advisory Group on Immunization (NTAGI): NTAGI advises on new vaccines and the expansion of the Universal Immunisation Programme (UIP), supports research to fill knowledge gaps, and monitors immunization program implementation and effectiveness.

Future of India’s Adult Vaccine Market

India’s adult vaccine market is poised for growth driven by increasing awareness and government initiatives. Rising health challenges, such as chronic diseases and infectious outbreaks, coupled with an aging population, will likely boost vaccine demand. Expanding vaccination programs and improved access to healthcare are expected to enhance market penetration. Additionally, advancements in vaccine technology and increased funding for adult immunization will contribute to market expansion, addressing gaps and improving public health outcomes.

Scope of Work for the India Adult Vaccine Market

Makreo Research presents a comprehensive report titled "India Adult Vaccine Market," offering an in-depth analysis of the market dynamics across India. This report assesses the impact of the country’s diverse economic, geographic, and healthcare landscapes, providing a detailed evaluation of both historical and current market performance, with a focus on key segments such as various disease categories and corresponding vaccines.

The report evaluates the influence of technological advancements and identifies key trends, including vaccine demand patterns based on disease prevalence in India. It further examines the factors driving market demand, such as healthcare facilities, vaccination programs, and the role of key end-user sectors. The analysis also includes an evaluation of vaccine demand and effectiveness in addressing public health concerns, alongside relevant government policies and regulations that shape market growth and development.

Additionally, the report offers an extensive analysis of the major players in the Indian adult vaccine market, including prominent companies such as Merck Group, Pfizer Ltd., Sanofi Pasteur, Serum Institute of India, and Bharat Biotech. It provides an in-depth review of these companies, covering recent vaccine developments, innovations, and detailed company profiles, offering stakeholders valuable insights into the competitive landscape and future opportunities within the market.

Market Assessment

The report delivers a thorough analysis of the India Adult Vaccine market, examining a range of market-related factors and offering valuable insights. It covers segment-wise dynamics, historical and current market performance, and relevant government initiatives and investments.

The report categorizes the market by types of vaccines, by states, by income groups and assesses the impact of technological advancements and innovations. It also provides an overview of investment trends and project costs, along with regional or state-wise developments across the reason.

Companies Covered

• Merck Group
• Pfizer Ltd.
• Sanofi Pasteur
• Serum Institute of India
• Bharat Biotech

Key Questions Answered

1. How is the vaccine market in India currently performing?

2. What are the anticipated revenue figures for the Indian vaccine market in the upcoming years?

3. What are the primary factors driving growth in the Indian vaccine market?

4. How does India's vaccine production capacity measure up against global standards?

5. What is the significance of the Universal Immunization Program (UIP) in the distribution of vaccines in India?

6. What major challenges do vaccine manufacturers in India encounter?

7. In what ways has the COVID-19 pandemic influenced vaccine development and distribution in India?

8. What is the regulatory landscape governing vaccine production and distribution in India?

9. Who are the leading companies in the Indian vaccine market?

10. What trends are emerging in consumer demand for vaccines in India?

11. How does the cost of vaccine production in India compare to that in other developing nations?

12. What support is the Indian government providing for vaccine research and development?

13. What future innovations are anticipated in the Indian vaccine sector?" Show more